Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Subcutaneous Versus Intravenous Immune Checkpoint Inhibitors, Treatment Burden, and Care Delivery for Patients With Renal Cell Carcinoma

NCT07872553 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT07872553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07872553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Subcutaneous Versus Intravenous Immune Checkpoint Inhibitors, Treatment Burden, and Care Delivery for Patients With Renal Cell Carcinoma
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
September 24, 2026
Completion date
September 24, 2030
Enrollment
40 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer, renal cell carcinoma